Poolbeg Pharma – New therapeutics and vaccines

Luke O’Niell commenting on Poolbeg Pharma’s access to a vast array of human challenge data to identify potential new therapeutics and vaccines.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Key AI trends in Drug Discovery

2023 was the year of AI. It would be difficult to finish your day without seeing or hearing at least 5 updates about developments related to AI, ChatGPT or language models. The year was marked by

DirectorsTalk

Companies to follow in 2024

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

5 ways pharma can safely leverage AI for drug discovery

In recent years, those applying computer science to biology have had no trouble raising the money to take their innovations straight into the commercial world. The promise was simple: get your hands on large datasets and

Poolbeg Pharma: Year in Review 2023

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg identifies strategic drug targets for treatment of RSV

Biopharmaceutical company Poolbeg has selected as strategic priority a number of potential treatments for Respiratory Syncytial Virus. The drug targets were selected from a list identified as part of Poolbeg’s artificial intelligence-led programme, which identified the

Poolbeg Pharma says used AI to identify RSV drug targets

Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). The programme identified the RSV drug treatment candidates in just 10 months, the company said

Poolbeg Pharma

How Generative AI is shaping the future of pharma

In the past year, generative artificial intelligence (GAI) has emerged as a potentially groundbreaking force in the pharmaceutical industry. This technology, which involves AI systems that can generate novel data and insights, could very well become